CIBC Private Wealth Group LLC Grows Position in AbbVie Inc. $ABBV

CIBC Private Wealth Group LLC raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,179,751 shares of the company’s stock after purchasing an additional 13,087 shares during the period. CIBC Private Wealth Group LLC’s holdings in AbbVie were worth $273,159,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie during the 2nd quarter worth $26,000. Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the third quarter valued at $31,000. Caitlin John LLC acquired a new position in AbbVie in the third quarter valued at $33,000. Delos Wealth Advisors LLC purchased a new stake in AbbVie during the second quarter valued at about $39,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in AbbVie during the third quarter valued at about $41,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Activity

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by insiders.

AbbVie Stock Down 5.1%

Shares of ABBV opened at $208.47 on Thursday. The firm has a market cap of $368.62 billion, a price-to-earnings ratio of 88.34, a PEG ratio of 0.76 and a beta of 0.34. The business’s 50 day moving average is $223.76 and its two-hundred day moving average is $224.84. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s payout ratio is presently 293.22%.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of research reports. Citigroup cut their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Evercore dropped their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. William Blair restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, Piper Sandler lifted their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Alloy Therapeutics signed a multi‑year collaboration with AbbVie to advance a next‑generation antibody discovery platform, providing upfront and milestone payments and potential pipeline upside. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: Legendary investor Ken Fisher has AbbVie among notable portfolio moves for 2026, signaling continued institutional interest that can support the stock over the medium term. AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
• Positive Sentiment: Zacks highlights AbbVie as a strong value pick based on style scores and fundamentals, which may attract value-oriented buyers amid short‑term weakness. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Neutral Sentiment: Technically, ABBV slipped below its 50‑day moving average, signaling short‑term weakness to traders but it remains above the 200‑day average, so the long‑term trend is intact. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
• Neutral Sentiment: Market commentary (MSN/Benzinga) notes the share move largely reflects competitor progress rather than new AbbVie-specific fundamentals—useful for context but not new company data. What’s Going On With AbbVie Stock Today?
• Neutral Sentiment: High‑level policy reporting shows TrumpRx price lists aren’t uniformly cheaper than the UK, a reminder of ongoing pricing and regulatory scrutiny in pharma but not an AbbVie‑specific action today. TrumpRx lists many medicines at prices higher than paid in UK
• Negative Sentiment: FDA approved J&J’s oral IL‑23 inhibitor (Icotyde), the first oral peptide that blocks IL‑23 and a direct competitive threat to Skyrizi/Tremfya; J&J expects this class could reach blockbuster sales, increasing pressure on AbbVie’s pricing and market share in psoriasis. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: several outlets report ABBV shares fell sharply today after the J&J approval, indicating investor concern about near‑term revenue impact for Skyrizi. AbbVie (ABBV) Shares Plunge Nearly 5% as FDA Clears J&J’s Rival Psoriasis Treatment
• Negative Sentiment: Legal risk: a U.S. appeals court revived a whistleblower suit accusing big drugmakers of overcharging programs for low‑income patients, reviving potential litigation and settlement exposure for major pharma names. Big drugmakers must face US overcharge claims on medications for low-income patients

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.